781: Greg Madison of Shield Therapeutics discusses their US expansion, final results & financing agreement


Manage episode 333488665 series 2936804
بواسطة Vox Markets Podcast، اكتشفه Player FM ومجتمعنا ـ حقوق الطبع والنشر مملوكة للناشر وليس لـPlayer FM، والصوت يبث مباشرة من خوادمه. اضغط زر الاشتراك لمتابعة التحديثات في Player FM، أو ألصق رابط التغذية الراجعة في أي تطبيق بودكاست آخر.
Greg Madison, CEO of Shield Therapeutics #STX discusses their US expansion which has seen a 100% increase in total Accrufer® prescriptions in Q1 '22 as compared to Q4 '21, their final results & financing agreement.
Current Business Updates

· 100% increase in total Accrufer® prescriptions in Q1 '22 as compared to Q4 '21, exceeding 3,900 total prescriptions during the first quarter, with a small 30-person sales team.
o Women's Health practitioners, a rapidly growing segment treating women with underlying diseases leading to iron deficiency, now represents over 50% of Accrufer® prescriptions.
o Continued high Accrufer® demand from the General Practitioners representing the balance of prescriptions.
o Estimated 20 million people in the US with anaemia reflecting a huge medical need.
· 100 million or ~40% of eligible lives now have coverage for Accrufer® by US payers across commercial and Medicaid segments, dramatically expanding access for patients and growing further.
· >1,100 Health Care Providers have been introduced to Accrufer® by participating in Shield sponsored programmes from January to April.
· 700 New First Time Writers of Accrufer® from January to April, indicating growing awareness and interest by healthcare providers.
· FDA approval of Accrufer® product shelf life increased from 24 to 36 months providing additional flexibility in manufacturing and storage timelines.
· Phase 3 paediatric study in the US and UK on track with over 50% of sites active.
· Out-licensing agreement for Accrufer®/Feraccru® with KYE Pharmaceuticals Inc. ("KYE") in Canada in January 2022. In March 2022, KYE submitted their documentation for approval in the Canadian market, expected mid-2023.

943 حلقات